Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic regulation of DUX4: From embryogenesis to muscular degeneration.

Current opinion in cell biology·2025
Same author

Future Microbiome Therapeutics for Clostridioides difficile Infection.

The American journal of gastroenterology·2023
Same author

Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension.

Science signaling·2022
Same author

Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.

Circulation research·2022
Same author

Correlation of Gastrointestinal Symptoms at Initial Presentation with Clinical Outcomes in Hospitalized COVID-19 Patients: Results from a Large Health System in the Southern USA.

Digestive diseases and sciences·2022
Same author

Tissue-Restricted Stem Cells as Starting Cell Source for Efficient Generation of Pluripotent Stem Cells: An Overview.

Advances in experimental medicine and biology·2021
Same journal

Continuous Glucose Monitoring and Early Dysglycemia: Toward an Emerging Stage Preceding Prediabetes.

Journal of diabetes science and technology·2026
Same journal

A Pilot Study on Disposal Practices and Environmental Awareness of Insulin-Related Devices Among People With Diabetes.

Journal of diabetes science and technology·2026
Same journal

Quality of In-Use Insulin Under Real-World Storage Conditions in Mwanza, Tanzania.

Journal of diabetes science and technology·2026
Same journal

Continuous Glucose Monitoring Metrics for Predicting Adverse Neonatal Outcomes in Individuals Undergoing Gestational Diabetes Screening.

Journal of diabetes science and technology·2026
Same journal

Diabetes Technologist: Optimal Use of Technology in Everyday Practice.

Journal of diabetes science and technology·2026
Same journal

AI-Driven Diabetes Care and Its Relevance in the Philippine Context: Opportunities and Persistent Digital Barriers.

Journal of diabetes science and technology·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Generic safety requirements for developing safe insulin pump software.

Yi Zhang1, Raoul Jetley, Paul L Jones

  • 1Office of Science and Engineering Laboratories, Center for Device and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland 20993, USA. Yi.Zhang2@fda.hhs.gov

Journal of Diabetes Science and Technology
|January 10, 2012
PubMed
Summary
This summary is machine-generated.

This study details generic safety requirements for insulin infusion pumps to enhance device safety. These requirements aim to improve insulin pump software design and reduce flaws for better diabetes care.

More Related Videos

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion
07:30

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Published on: December 13, 2024

Related Experiment Videos

Last Updated: May 26, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion
07:30

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Published on: December 13, 2024

Area of Science:

  • Biomedical Engineering
  • Medical Device Safety
  • Software Engineering

Background:

  • Previous work introduced a generic insulin infusion pump (GIIP) model identifying common features and hazards.
  • This study extends the GIIP model by defining safety requirements for identified hazards.

Purpose of the Study:

  • To articulate safety requirements for the GIIP model.
  • To provide a safety reference for insulin pump software development.
  • To foster discussion on insulin pump safety within the diabetes community.

Main Methods:

  • Established a generic insulin pump architecture abstracting common functions.
  • Conducted a preliminary hazard analysis with domain expert consultations.
  • Developed safety requirements through further expert consultation for modeling.

Main Results:

  • Presented generic safety requirements for the GIIP model.
  • Requirements are parameterized for clinical practices and specific device criteria.
  • Ensures safe device performance and reliable insulin delivery.

Conclusions:

  • Generic safety requirements offer value for diabetes, academic, and manufacturing communities.
  • Requirements can be extended, revised, and used for assessing insulin pump software safety.
  • Integrating requirements with model-based engineering (MBE) can reduce flaws and improve safety.